Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...

Related Keywords

Christina Tartaglia ,John Quisel ,Nasdaq ,Disc Medicine Inc ,Verge Scientific Communications ,Exchange Commission ,Patient Global Impression ,Chief Executive ,Erythropoietic Protoporphyria ,X Linked Protoporphyria ,Private Securities Litigation Reform Act ,Annual Report ,